Bimekizumab 4-year Maintenance of Responses in Week 16 Responders with Moderate to Severe Plaque Psoriasis: Results from the BE BRIGHT Open-label Extension Phase 3 Trial. J of Skin. 2024;8(6):s437. doi:10.25251/skin.8.supp.437